compound semaglutide being discontinued FDA crackdown on off-brand Ozempic products set to take effect, threatening supply and access for many Weight Watchers stopped supplying semaglutide:

Retatrutide Retatrutide is an investigational metabolic treatment developed by Eli Lilly

Organizations like Finnrick Analytics have begun to address this imbalance, but independent testing coverage remains limited to a fraction of available products and vendors

Retatrutide remains an investigational compound, so any Retatrutide dose escalation schedule found online should be treated as general background reading rather than a prescribing instruction

Managing Digestive Side Effects on GLP-1 Treatment Most gastrointestinal side effects associated with GLP-1 therapy are mild to moderate and tend to improve over time as the body adjusts to treatment

No, GLP-1 patches do not work as advertised

For example, if a beneficiary initiated GLP-1 therapy in September 2024 with a body mass index (BMI) of 37 and has a BMI of 34 at the time of a July 2026 prior authorization request, the prescribing provider should attest that the beneficiary met the BMI 35 criterion at the time therapy was initiated